Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells

BACKGROUND: About 75–80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Padró, Mercè, Louie, Raymond J., Lananna, Brian V., Krieg, Adam J., Timmerman, Luika A., Chan, Denise A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358051/
https://www.ncbi.nlm.nih.gov/pubmed/28320353
http://dx.doi.org/10.1186/s12885-017-3140-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358051/
https://www.ncbi.nlm.nih.gov/pubmed/28320353
http://dx.doi.org/10.1186/s12885-017-3140-9

Ejemplares similares